Results 211 to 220 of about 20,899 (290)

A transcriptomics-based drug repositioning approach to identify drugs with similar activities for the treatment of muscle pathologies in spinal muscular atrophy (SMA) models. [PDF]

Hum Mol Genet
Hoolachan JM, McCallion E, Sutton ER, Çetin Ö, Pacheco-Torres P, Dimitriadi M, Sari S, Miller GJ, Okoh M, Walter LM, Claus P, Wood MJA, Tonge DP, Bowerman M.   +13 more
europepmc   +1 more source

The Need for SMN-Independent Treatments of Spinal Muscular Atrophy (SMA) to Complement SMN-Enhancing Drugs. [PDF]

Front Neurol, 2020
Hensel N, Kubinski S, Claus P.
europepmc   +1 more source

Spinal muscular atrophy (SMA).

Neurosciences (Riyadh, Saudi Arabia), 2011
Abdulaziz, Al-Saman, Osama, Mudhafar
openaire   +1 more source

Skeletal Muscle DNA Damage Precedes Spinal Motor Neuron DNA Damage in a Mouse Model of Spinal Muscular Atrophy (SMA)

, 2014
Saniya Fayzullina, Lee J. Martin
openalex   +2 more sources

Onasemnogene Abeparvovec: Post-infusion Efficacy and Safety in Patients With Spinal Muscular Atrophy (SMA)-A Fondazione Policlinico Gemelli IRCCS Experience. [PDF]

Hosp Pharm
Favia M, Tarantino D, Cerbo LD, Sabia A, Campopiano R, Pani M.   +5 more
europepmc   +1 more source

Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study [PDF]

, 2016
Connolly, Anne M, et al,
core   +2 more sources

908. Lentiviral Vector-Mediated Transduction in Murine SMA Embryonic Stem Cells Derived from Spinal Muscular Atrophy (SMAI) Mice [PDF]

, 2010

openalex   +1 more source

Routine Cerebrospinal Fluid (CSF) Parameters in Patients With Spinal Muscular Atrophy (SMA) Treated With Nusinersen. [PDF]

Front Neurol, 2019
Wurster CD, Koch JC, Cordts I, Dreyhaupt J, Otto M, Uzelac Z, Witzel S, Winter B, Kocak T, Schocke M, Weydt P, Wollinsky K, Ludolph AC, Deschauer M, Lingor P, Tumani H, Hermann A, Günther R.   +17 more
europepmc   +1 more source

Rights of Children Suffering from SMA (Spinal Muscular Atrophy) [PDF]

e-Pedagogium, 2010
openaire   +1 more source

Machine learning predicts treatment response to nusinersen in non-sitter Spinal Muscular Atrophy (SMA).

Stimpson G, O'Reilly E, Coratti G, Ridout D, Chakraborti T, Mitra R, de Sanctis R, Pane M, Scoto M, Mercuri E, Muntoni F, Baranello G, International SMA Consortium.   +12 more
europepmc   +1 more source